HC Wainwright & Co. Reiterates Buy on Collegium Pharmaceutical, Maintains $60 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and maintains $60 price target.